Outcomes und endpoints
death, hypertension, infections
INFECTIONS, RECURRENT PNEUMONIA, SECONDARY, PULMONARY INFECTIONS, HYPERTENSION, SECONDARY INFECTION
The objective of this analysis was to investigate differences in outcome until 180 days after adjunct prednisone or placebo in CAP. Specifically, we analysed the two treatment groups for differences in the following primary and secondary endpoints. Furthermore, subgroup analysis for predefined endpoints was performed.The primary endpoint was defined as time to death from any cause.Secondary endpoints included CAP-related death, readmission, recurrent pneumonia, secondary infections, new hypertension at day 180 and new insulin dependence at day 180.Types of secondary infections were categorized as dermatological, urogenital, pulmonary, intestinal, and endocardium/ foreign body infections, as well as a group of combined urogenital and pulmonary infections. The last group was formed due to the frequent issue of the two infections often occurring simultaneously.In the original trial protocol, the primary outcome was time to clinical stability. Secondary endpoints in the original protocol were all-cause mortality, time to effective hospital discharge, and side effects of corticosteroid treatments, among others [